AST-120: Clinical Trials

13 trials of AST-120, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

11 completed, 2 terminated. 6 Phase 2, 4 Phase 4, 3 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	6	Completed 4, Terminated 2
Phase 4	4	Completed 4
Phase 3	3	Completed 3

Follow AST-120: new trials by email Literature Review of AST-120 trials Research Report on AST-120

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
AST-120 in Hemodialysis Patients With Uremic Pruritus AST-120 - Uremic Pruritus	Phase 4	Completed	Conmed Pharmaceutical & Bio-Medical Corporation	100	2020-07-02	2023-09-07
Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammation Kremezin - Loss of Solute Clearance	Phase 4	Completed	Tungs' Taichung Metroharbour Hospital	30	2011-01-01	2014-05-09
AST-120 Used to Treat Mild Hepatic Encephalopathy AST-120 - Mild Hepatic Encephalopathy	Phase 2	Completed	Ocera Therapeutics	148	2009-03-01	2014-06-18
Kremezin Study Against Renal Disease Progression in Korea AST-120 - Chronic Kidney Disease	Phase 4	Completed	Seoul National University Hospital	578	2009-03-01	2014-03-19
Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients. AST-120 - Chronic Kidney Disease, AST-120	Phase 4	Completed	Chang Gung Memorial Hospital	51	2009-01-01	2013-08-06
Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI AST-120, Celphere CP-305 - Gastroesophageal Reflux Disease (GERD)	Phase 2	Terminated	Ocera Therapeutics	4	2007-10-01	2014-06-18
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy AST-120, lactulose - Hepatic Encephalopathy	Phase 2	Completed	Ocera Therapeutics	40	2007-09-01	2014-05-30
Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome AST-120, Celphere® CP-305 - Irritable Bowel Syndrome	Phase 2	Completed	Ocera Therapeutics	117	2007-08-01	2014-06-18
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1) Placebo, AST-120 - Chronic Kidney Disease	Phase 3	Completed	Tanabe Pharma Corporation	1020	2007-07-01	2026-01-08
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2) Placebo, AST-120 - Chronic Kidney Disease	Phase 3	Completed	Tanabe Pharma Corporation	1015	2007-07-01	2026-01-08
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis AST-120 - Pouchitis	Phase 2	Terminated	Ocera Therapeutics	2	2007-03-01	2014-06-18
Safety and Efficacy of AST-120 in the Treatment of Pouchitis AST-120 - Pouchitis	Phase 2	Completed	Ocera Therapeutics	19	2007-02-01	2014-06-18
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas AST-120 - Inflammatory Bowel Disease, Intestinal Fistula	Phase 3	Completed	Ocera Therapeutics	191	2006-03-01	2014-05-30

Conditions studied

Sponsors

Countries

Top investigators

Results publications